Unlock instant, AI-driven research and patent intelligence for your innovation.

Liver cancer serum marker CPE (carboxypeptidase E)

A technology of markers and diagnostic markers, applied in the field of laboratory medicine

Active Publication Date: 2018-09-25
ZHIHUI MEDICAL TECH (SHANGHAI) CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the use of CPE as a serum marker for liver cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liver cancer serum marker CPE (carboxypeptidase E)
  • Liver cancer serum marker CPE (carboxypeptidase E)
  • Liver cancer serum marker CPE (carboxypeptidase E)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1: CPE expression is affected by TFCP2 and YAP

[0057] We first examined whether expression of the membrane protein CPE was affected by YAP and TFCP2. The results of qPCR experiments showed that the overexpression of YAP and TFCP2 in the cell lines 7402 and 7721 with high malignant degree of liver cancer could promote the mRNA expression level of CPE, while the co-overexpression of YAP and TFCP2 could significantly promote the mRNA expression level of CPE ( figure 1 ). Knockdown of YAP or TFCP2 can also inhibit the mRNA expression of CPE, respectively, and knockdown of YAP and TFCP2 can inhibit the mRNA expression of CPE more significantly ( figure 2 ). Through the results of western blot experiments, we found that the overexpression of YAP and TFCP2 also promoted the expression of CPE protein ( image 3 ), while the knockdown of YAP and TFCP2 could inhibit the expression of CPE protein ( Figure 4 ). We found a TFCP2 transcription factor binding motif (T...

Embodiment 2

[0058] Example 2: CPE expression level in serum is specifically up-regulated in liver cancer

[0059] Since both TFCP2 and YAP are key molecules that promote liver cancer-related transcriptional signals, we speculate that the membrane protein CPE, as their target gene, may be expressed in large quantities in liver cancer and released into the blood. After testing, it was found that in the serum of 147 patients with liver cancer, the expression level of CPE was 813.084±199.118pg / ml, which was significantly higher than that of 100 normal people (41.55±9.074pg / ml). In addition, we selected benign liver disease hepatitis B and other digestive tract tumors and gastric cancer as controls, and found that the expression levels of CPE in patients with hepatitis B (32.493±7.019pg / ml, n=42) and gastric cancer (53.147±13.155pg / ml, n=29) had no significant difference compared with the normal population, and was significantly lower than that of patients with liver cancer ( Figure 8 ). Th...

Embodiment 3

[0060] Example 3: There is a certain correlation between the expression level of CPE in serum and the classic liver function indicators

[0061] AFP is a classic serum marker of liver cancer. We found that there was a significant positive correlation between the expression of CPE and AFP (R=0.644, p=0.000). In addition, there was a correlation between CPE expression and classic liver function indexes alanine aminotransferase ALT (R=0.454, p=0.000) and aspartate aminotransferase AST (R=0.351, p=0.001) ( Figure 9 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention relates to a new application of CPE (carboxypeptidase E) serving as a liver cancer serum marker. The liver cancer serum marker CPE has the advantage that the rise expression of the CPE in serum of liver cancer patients has certain specificity, and the expression level of the CPE in serum has certain correlation with the classical liver function indexes (AFP, ALT and AST). Compared with the AFP, the CPE is a better liver cancer serological marker, the area under the ROC curve of the CPE is 0.937, and the area under the ROC curve of the AFP is 0.679. The optimal diagnostic threshold of the CPE is 75pg / ml, the sensitivity is 90.7%, and the specificity is 97.5%.

Description

technical field [0001] The invention relates to the technical field of laboratory medicine, in particular to a new serum marker for liver cancer. Background technique [0002] Liver cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Due to the lack of highly specific and sensitive early diagnostic markers, patients with liver cancer usually cannot receive timely treatment. The classic diagnostic markers for liver cancer currently used in clinical diagnosis include alpha-fetoprotein (AFP), alpha-fetoprotein variant (AFP-L3), de-carboxyprothrombin (DCP) and so on. However, there is still room for improvement in the sensitivity and specificity of these diagnostic markers, which makes the problem of false positives and false negatives in the early diagnosis of liver cancer more serious. The development of new diagnostic markers for liver cancer has an extremely important role in the early treatment of liver cancer patients and in reduci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68
CPCG01N33/574G01N33/57438G01N33/57484G01N33/6893G01N2333/4746
Inventor 王佳谊张骁郭素素杨月月孙奋勇陈岩潘秋辉乔永霞
Owner ZHIHUI MEDICAL TECH (SHANGHAI) CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com